A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: For advanced breast cancer in postmenopausal patients

PharmacoEconomics

Volumn 21, Issue 7, 2003, Pages 513-525

  Karnon, Jon ^a   Jones, Trefor ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Novartis Pharmaceuticals UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; STOCHASTIC MODEL;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MARKOV CHAINS; MODELS, BIOLOGICAL; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; STOCHASTIC PROCESSES; TAMOXIFEN; TRIAZOLES;

EID: 0038554367     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321070-00006     Document Type: Article

References (25)

1. Cancer Research Campaign. Fact sheet 1: incidence. London: CRC Publications, 1998
2. Harris, JR, Morrow M, Bonadonna G. Cancer of the breast. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: Lippincott Co, 1993
3. Haller DG, Fox KR, Schuchter LM. Metastatic breast cancer. In: Fowble B, Goodman RL, Glick JH, Rosato EF, editors. Breast cancer treatment: a comprehensive guide to management. St Louis: Mosby Year Book, 1991
4. Muss HB. Endocrine therapy for advanced breast cancer. Breast Cancer Res Treat 1992; 21: 15-26
5. Leonard RC, Rodger A, Dixon JM. ABC of breast diseases: metastatic breast cancer. BMJ 1994; 309 [6967]: 1501-4
6. Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 2001; 77 (2): 139-47
7. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998; 4 (3): 527-34
8. Buzdar AU. Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer 1999; 6 (2): 219-25
9. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of Letrozole versus Tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19 (10): 2596-606
10. HM Treasury. Appraisal and evaluation in central government. London: HMSO, 1997
11. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18 (18): 3302-17
12. Nuijten M, Meester L, Waibel F, et al. Cost effectiveness of Letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics 1999; 16 (4): 379-97
13. NHS Executive. The new NHS 2000 reference costs. London: Department of Health, 2000
14. British National Formulary 40. London: Bristish Medical Association/Royal Pharmaceutical Society of Great Britain, 2000 September
15. NHSE. Costing for contracting. Costed HRGs: evaluation summary report. Leeds: NHSE, 1995
16. Nuijten M, McCormick J, Waibel F, et al., Economic evaluation of Letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value in Health 2000; 3 (1): 31-9
17. Netten A, Curtis L.Unit costs of health and social care 2000. PSSRU: University of Kent, 2000
18. Briggs AH. A bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999; 8 (3): 257-61
19. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making 1998; 18 (1): 95-109
20. Iverson GR. Bayesian statistical inference. Thousand Oaks (CA): Sage, 1984
21. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500
22. Briggs A, Fenn P. Confidence intervals or surfaces?: uncertainty on the cost-effectiveness plane. Health Econ 1998; 7 (8): 723-40
23. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996; 9 Suppl. 2: 8-22
24. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA 1992; 267 (15): 2055-61
25. de Haes JC, de Koning HJ, van Oortmarssen GJ, et al. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer 1991; 49 (4): 538-44